Last day at Eurotox 2017 ! I was very impressed by the enthousiasm of the community these past 2 days. A lot of tremending studies were presented, conforting our will to pursue our toxicology assay development. Last workshop will talk about advanced liver model integration for chemical safety assesment, and I am impatient to attend it !
Great start for Eurotox 2017 ! Congress has begun with a lovely opening ceremony with traditional slovakian dancers. The first keynote of professor Philip Steven was a passionated overview of neurosciences between non-human and human research, performed in neurovigil team between NASA and MIT.
I am very excited to attend the following sessions! If you want to meet me, don’t hesitate to contact me!
We are really happy to participate in the 53rd Congress of the European Societies of Toxicology to be held in Bratislava from the 10th to the 13th of September, 2017.
This year, the scientific program is again very exciting and we look forward to attending the conferences, especially in genotoxicity, skin toxicity and stem cells.
If you want to plan a side-meeting interview, don’t hesitate to contact us.
See you next week !
Idiosyncratic drug-induced liver injury (DILI) is a rare adverse drug reaction resulting in liver injury, and a cause of failure in both clinical and post-approval stages of drug development. Predictive the toxicity of new chemicals entities (NCE) is a key challenge to the pharmaceutical industry (FDA, 2009). In order to avoid the use of laboratory animals, and to reduce the cost of pre clinical studies, in vitro toxicology combined the use of cellular models with the measurements of several cell health endpoints in order to predict the hepatotoxicity of NCE. Primary Human Hepatocytes and heptocyte-like cell lines such as HepaRG, Upcytes and HepG2 are commonly used in NCE safety assessment. However, standard cellular assays have shown their limitation to specifically predict DILI potential of NCE (Sison-Young et al., 2017). The era of high content analysis, and especially phenotypic screening, bring new strategy for toxicologist to predict DILIs and their underlying mechanisms, and provides an effective means to reduce drug development failures due to insufficient safety (Xu, 2015).
- FDA (2009). Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation.
- Sison-Young, R.L., Lauschke, V.M., Johann, E., Alexandre, E., Antherieu, S., Aerts, H., Gerets, H.H.J., Labbe, G., Hoët, D., Dorau, M., et al. (2017). A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity. Arch. Toxicol. 91, 1385–1400.
- Xu, J.J. (2015). Cellular imaging: a key phenotypic screening strategy for predictive toxicology. Front. Pharmacol. 6.
It has been a very fruitfull event regarding both the scientific content and the networking possibilities. Very intense and complete sessions about state of the art regarding in vitro toxicology models and toxicology science were held for the 4 days of the event.
Among all the very good and informative presentations, we were really glad to attend the ones done by collaborators HCS Pharma work with. Also, a poster, showing the results obtained from a collaborative work between HCS Pharma and Galderma, has been presented and discussed with visitors interested in genotoxicity assessment. This poster, about assessment of primary DNA damages with gammaH2AX and comet assays on primary human keratinocytes, is now accessible on demand !
We thank all the scientists we met, either those with whom HCS Pharma already collaborate, the ones with whom we have personnaly worked in the past, and those with whom we had interesting discussions !
To conclude, an aphorism from George Box, dated back to the 70’s, has been cited many times : “All models are wrong, but some are useful.” Among the described futur useful models, many involved 3D culture methods, microfluidics and/or co-culture, with cell lines or stem cells, to better mimic the in vivo situation. Very nice developments were shown, among others, about liver and neuronal models. It strengthens the direction HCS Pharma has taken, as we already have an expanding expertise in these fields.
We are very happy to present you Pierre-Jean Ferron, who joined HCS Pharma as a study director, specialized in cellular biology and high content analysis.
After a master degree in cellular biology and cellular toxicology at Rennes University, Pierre-Jean realized a Ph.D at the Frenh Agency for Food and Safety. During his Ph.D Pierre-Jean has developped high content toxicology assay, based on the use of pertinent cell lines models to study human cytotoxicity of phycotoxins. He then began a post doc in collaboration with the French Institute for Agricultural Research where he studied the toxicological impact of meat contaminants on human cells. For those years, Pierre-Jean has developped strong knowledge in cellular biology and high content analysis, and published several scientific papers.
Genetic Engineering & Biotechnology News (GEN) organise a free webinar about HCS ans HCA use in drug toxicity and genotoxicity testing.
High-content analysis (HCA) and high-content screening (HCS) enable imaging of large numbers of cellular samples for a variety of life science applications. Using automated high-resolution microscopy coupled with analytical software to visualize and quantify phenotypic responses in cells, HCS determines how compounds such as small molecule drugs, antibodies, or siRNA, affect cell morphology in a rapid, quantitative, high-throughput manner, providing meaningful functional readouts of cellular activity.
The broadcast date is Wednesday, June 11, 2014 at 10:00 am ET, 7:00 am PT, 4:00 pm CEST.